Leidos has been initiated with a Neutral rating by UBS, which set a price target of $182, citing a strong book-to-bill ratio and a solid growth trajectory despite expected slower growth in 2025. The company recently secured a $235 million contract to modernize the Organ Procurement and Transplant Network and reported a record adjusted EBITDA margin of 14.2% in Q3 2024, raising its revenue guidance for the year. Meanwhile, JPMorgan increased its price target to $205, reflecting strong performance in the Federal IT sector, particularly in Health & Civil services.